{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wormeyer L"],"funding":["Deutsche Forschungsgemeinschaft","Heinrich-Heine-Universität Düsseldorf","University Hospital Düsseldorf, Medical Faculty"],"pagination":["223-234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10901624"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["56(3)"],"pubmed_abstract":["For treatment of type 1 diabetes mellitus, a combination of immune-based interventions and medication to promote beta-cell survival and proliferation has been proposed. Dextromethorphan (DXM) is an <i>N</i>-methyl-D-aspartate receptor antagonist with a good safety profile, and to date, preclinical and clinical evidence for blood glucose-lowering and islet-cell-protective effects of DXM have only been provided for animals and individuals with type 2 diabetes mellitus. Here, we assessed the potential anti-diabetic effects of DXM in the non-obese diabetic mouse model of type 1 diabetes. More specifically, we showed that DXM treatment led to five-fold higher numbers of pancreatic islets and more than two-fold larger alpha- and beta-cell areas compared to untreated mice. Further, DXM treatment improved glucose homeostasis and reduced diabetes incidence by 50%. Our data highlight DXM as a novel candidate for adjunct treatment of preclinical or recent-onset type 1 diabetes."],"journal":["Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme"],"pubmed_title":["The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice."],"pmcid":["PMC10901624"],"funding_grant_id":["434472323"],"pubmed_authors":["Wormeyer L","Mayatepek E","Uhlemeyer C","Welters A","Nortmann O","Eberhard D","Meissner T","Lammert E","Belgardt B","Hamacher A"],"additional_accession":[]},"is_claimable":false,"name":"The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice.","description":"For treatment of type 1 diabetes mellitus, a combination of immune-based interventions and medication to promote beta-cell survival and proliferation has been proposed. Dextromethorphan (DXM) is an <i>N</i>-methyl-D-aspartate receptor antagonist with a good safety profile, and to date, preclinical and clinical evidence for blood glucose-lowering and islet-cell-protective effects of DXM have only been provided for animals and individuals with type 2 diabetes mellitus. Here, we assessed the potential anti-diabetic effects of DXM in the non-obese diabetic mouse model of type 1 diabetes. More specifically, we showed that DXM treatment led to five-fold higher numbers of pancreatic islets and more than two-fold larger alpha- and beta-cell areas compared to untreated mice. Further, DXM treatment improved glucose homeostasis and reduced diabetes incidence by 50%. Our data highlight DXM as a novel candidate for adjunct treatment of preclinical or recent-onset type 1 diabetes.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-22T06:38:03.891Z","creation":"2025-04-05T21:48:21.671Z"},"accession":"S-EPMC10901624","cross_references":{"pubmed":["38168730"],"doi":["10.1055/a-2236-8625"]}}